FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W151938067> ?p ?o ?g. }

• W151938067 abstract "Abstract Background The assessment of residual tumor cells persisting after therapy, or minimal residual disease (MRD), is a central component of accurate disease prognosis in acute lymphoblastic leukemia (ALL) (Pui et al, JCO 2011). MRD assessment has recently been shown to be useful for monitoring disease before and after stem cell transplantation and during salvage therapy for early detection of an imminent relapse (Bruggemann et al., SemOncol 2012). Allele-specific oligonucleotide (ASO)-PCR can be used to assess MRD; however, this technique requires preparation of clonotype-specific primers for each individual which is laborious and time-consuming. We recently demonstrated the utility of sequencing-based MRD assessment in lymphoid malignancies (Faham et al., Blood 2012). This quantitative approach, termed the LymphoSIGHT™ platform, relies on amplification and sequencing of immunoglobulin and T-cell receptor gene segments using consensus primers and can address some of the limitations associated with traditional MRD detection techniques. This sequencing platform has a sensitivity to detect one cancer cell per million leukocytes in peripheral blood and bone marrow samples. In this retrospective study, we evaluated the ability of the sequencing and ASO-PCR methods to detect MRD prior to clinical relapse in 17 patients with childhood ALL. Methods Using the sequencing assay, we analyzed bone marrow and/or peripheral blood samples collected at the diagnostic and relapse time points from 17 childhood ALL patients. Diagnostic and relapse samples were assessed for clonal rearrangements of immunoglobulin (IGH-VDJ, IGH-DJ, IGK) and T cell receptor (TRB, TRD, TRG) genes. Following identification of leukemia specific clonotype(s), we measured the corresponding MRD levels in 66 follow-up samples that were collected prior to clinical relapse. We analyzed the time from MRD positivity to clinical relapse for each patient using the sequencing and ASO-PCR methods. Results Sequencing detected the presence of a high-frequency clonal rearrangement of at least one receptor (“calibrating receptor”) in all the 17 childhood ALL patients; all patients had at least 2 calibrating receptors at diagnosis and/or relapse, 15 patients had at least 3 calibrating receptors, and 6 patients had 4 or more. The IGH-VDJ and TRG assays were the most frequent gene rearrangement: at least one IGH-VDJ and/or TRG clonal rearrangement was detected in 13 ALL patients. TRD was the third most informative receptor, with clonal rearrangements being detected in 11 patients. In the majority of patients, most leukemic clones identified at diagnosis were also present at high levels in the relapse sample. We analyzed the time from MRD positivity to clinical relapse in the patient cohort. In 2 patients (Figure 1, Patients G and P), we observed MRD positivity by sequencing 16 and 6.5 months prior to relapse, respectively. ASO-PCR also detected MRD positivity in Patient P at the 6.5 month time point. In 6 patients there was a sample collected within 1-3 months prior to relapse, and sequencing detected MRD in 4 of these patients (67%, Figure 1 Patients B, A, R, I), while ASO-PCR detected MRD in 2 of the 6 patients (33%, Figure 1 Patients B, R). Conclusions The clinical value of monitoring MRD by ASO-PCR for assessment of treatment response and outcome has been established in multiple lymphoid malignancies. This preliminary study provides further support for the sequencing-based MRD monitoring in ALL patients. This new approach offers improvements over ASO-PCR in the ability to monitor multiple clonal sequences and in the sensitivity to detect the leukemic cell. Thus, the sequencing method represents a new potential approach for MRD monitoring. However a larger number of patients must be analyzed to support its clinical application. Disclosures: Faham: Sequenta, Inc.: Employment, Equity Ownership, Membership on an entity’s Board of Directors or advisory committees. Pepin:Sequenta, Inc.: Employment, Equity Ownership. Carlton:Sequenta, Inc.: Employment, Equity Ownership." @default.
• W151938067 created "2016-06-24" @default.
• W151938067 creator A5000288435 @default.
• W151938067 creator A5003912397 @default.
• W151938067 creator A5016948495 @default.
• W151938067 creator A5028411277 @default.
• W151938067 creator A5039333571 @default.
• W151938067 creator A5051981929 @default.
• W151938067 creator A5054826901 @default.
• W151938067 creator A5064631593 @default.
• W151938067 creator A5070232314 @default.
• W151938067 date "2013-11-15" @default.
• W151938067 modified "2023-09-28" @default.
• W151938067 title "Minimal Residual Disease Monitoring In Acute Lymphoblastic Leukemia Patients Using Immune Receptor Sequencing" @default.
• W151938067 doi "https://doi.org/10.1182/blood.v122.21.1381.1381" @default.
• W151938067 hasPublicationYear "2013" @default.
• W151938067 type Work @default.
• W151938067 sameAs 151938067 @default.
• W151938067 citedByCount "0" @default.
• W151938067 crossrefType "journal-article" @default.
• W151938067 hasAuthorship W151938067A5000288435 @default.
• W151938067 hasAuthorship W151938067A5003912397 @default.
• W151938067 hasAuthorship W151938067A5016948495 @default.
• W151938067 hasAuthorship W151938067A5028411277 @default.
• W151938067 hasAuthorship W151938067A5039333571 @default.
• W151938067 hasAuthorship W151938067A5051981929 @default.
• W151938067 hasAuthorship W151938067A5054826901 @default.
• W151938067 hasAuthorship W151938067A5064631593 @default.
• W151938067 hasAuthorship W151938067A5070232314 @default.
• W151938067 hasConcept C104317684 @default.
• W151938067 hasConcept C126322002 @default.
• W151938067 hasConcept C143998085 @default.
• W151938067 hasConcept C159654299 @default.
• W151938067 hasConcept C203014093 @default.
• W151938067 hasConcept C2778461978 @default.
• W151938067 hasConcept C2779823535 @default.
• W151938067 hasConcept C2780007613 @default.
• W151938067 hasConcept C2781107101 @default.
• W151938067 hasConcept C2909962599 @default.
• W151938067 hasConcept C2911091166 @default.
• W151938067 hasConcept C49105822 @default.
• W151938067 hasConcept C54355233 @default.
• W151938067 hasConcept C71924100 @default.
• W151938067 hasConcept C86803240 @default.
• W151938067 hasConceptScore W151938067C104317684 @default.
• W151938067 hasConceptScore W151938067C126322002 @default.
• W151938067 hasConceptScore W151938067C143998085 @default.
• W151938067 hasConceptScore W151938067C159654299 @default.
• W151938067 hasConceptScore W151938067C203014093 @default.
• W151938067 hasConceptScore W151938067C2778461978 @default.
• W151938067 hasConceptScore W151938067C2779823535 @default.
• W151938067 hasConceptScore W151938067C2780007613 @default.
• W151938067 hasConceptScore W151938067C2781107101 @default.
• W151938067 hasConceptScore W151938067C2909962599 @default.
• W151938067 hasConceptScore W151938067C2911091166 @default.
• W151938067 hasConceptScore W151938067C49105822 @default.
• W151938067 hasConceptScore W151938067C54355233 @default.
• W151938067 hasConceptScore W151938067C71924100 @default.
• W151938067 hasConceptScore W151938067C86803240 @default.
• W151938067 hasLocation W1519380671 @default.
• W151938067 hasOpenAccess W151938067 @default.
• W151938067 hasPrimaryLocation W1519380671 @default.
• W151938067 hasRelatedWork W11718440 @default.
• W151938067 hasRelatedWork W1495924730 @default.
• W151938067 hasRelatedWork W2045807214 @default.
• W151938067 hasRelatedWork W2122514733 @default.
• W151938067 hasRelatedWork W2306410245 @default.
• W151938067 hasRelatedWork W2462520966 @default.
• W151938067 hasRelatedWork W2472559326 @default.
• W151938067 hasRelatedWork W2559927347 @default.
• W151938067 hasRelatedWork W2560561384 @default.
• W151938067 hasRelatedWork W2564698559 @default.
• W151938067 hasRelatedWork W2586277785 @default.
• W151938067 hasRelatedWork W2888339704 @default.
• W151938067 hasRelatedWork W2979693154 @default.
• W151938067 hasRelatedWork W2979716062 @default.
• W151938067 hasRelatedWork W2985064900 @default.
• W151938067 hasRelatedWork W314497249 @default.
• W151938067 hasRelatedWork W3212568259 @default.
• W151938067 hasRelatedWork W567351695 @default.
• W151938067 hasRelatedWork W64972836 @default.
• W151938067 hasRelatedWork W84633733 @default.
• W151938067 isParatext "false" @default.
• W151938067 isRetracted "false" @default.
• W151938067 magId "151938067" @default.
• W151938067 workType "article" @default.